問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間:2023-09-19

陽光耀YANG, KUANG-YAO
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

篩選

List

35Cases

2025-11-01 - 2030-12-31

Phase II

Not yet recruiting
A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  • Condition/Disease

    Chronic obstructive pulmonary disease

  • Test Drug

    prefilled syringe

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2022-12-15 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2012-05-30 - 2013-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2022-01-31 - 2024-12-10

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-09-01 - 2025-02-14

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-02-01 - 2026-06-22

Phase III

Active
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)
  • Condition/Disease

    Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)

  • Test Drug

    Amikacin liposome inhalation suspension (ALIS)

Participate Sites
12Sites

Not yet recruiting6Sites

Recruiting2Sites

Terminated4Sites

2023-06-01 - 2025-06-23

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2023-08-31 - 2032-02-12

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2020-11-02 - 2024-04-30

Phase III

Completed
A phase 3, randomized, double-blind, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of Brensocatib administered once a day to subjects with non-cystic fibrosis bronchiectasis for 52 weeks – ASPEN test
  • Condition/Disease

    Non-cystic fibrotic bronchiectasis

  • Test Drug

    Brensocatib (INS1007)

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4